A. Laster

发表

Antibody against T lymphoblastic leukemia-associated antigen (3-40) identifies vimentin and keratin intermediate filaments in normal cells.

B. Haynes, B. Dupont, T. Palker, 1985 .

The human thymic microenvironment: thymic epithelium contains specific keratins associated with early and late stages of epidermal keratinocyte maturation.

B. Haynes, T. Palker, A. Laster, 1986, Differentiation; research in biological diversity.

Clinical Value of Monitoring BMD in Patients Treated With Bisphosphonates for Osteoporosis

P. Geusens, N. Watts, R. Recker, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Duration of treatment in postmenopausal osteoporosis: how long to treat and what are the consequences of cessation of treatment?

A. Laster, S. B. Tanner, 2011, Rheumatic diseases clinics of North America.

Update on Rationale and Development of New Agents for the Treatment of Osteoporosis

R. Recker, J. Bilezikian, P. Miller, 2010 .

2009 Santa Fe Bone symposium.

R. Recker, J. Bilezikian, P. Miller, 2010, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Polyspecific reactivity of a murine monoclonal antibody that binds to nuclear matrix-associated, chromatin-bound autoantigens.

B. Haynes, D. Pisetsky, A. Laster, 1987, Clinical immunology and immunopathology.

Group B streptococcal arthritis in adults.

M. Michels, A. Laster, 1984, The American journal of medicine.

Genetic factors predisposing to chronic lymphocytic leukemia and to autoimmune disease.

C. Conley, A. Laster, J. Misiti, 1980, Medicine.

2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis: Comment on the Article by Buckley et al

M. Maricic, C. Deal, A. Laster, 2018, Arthritis care & research.

identifies vimentin and keratin intermediate filaments in normal cells Antibody against T lymphoblastic leukemia-associated antigen (3-40)

B. Haynes, T. Palker, A. Laster, 2011 .

Antibody 3–40 Binds to Keratin and Vimentin Intermediate Filaments

B. Haynes, T. Palker, A. Laster, 1986 .

Chronic immune thrombocytopenic purpura in monozygotic twins: genetic factors predisposing to ITP.

W. Bias, T. Kickler, C. Conley, 1982, The New England journal of medicine.

A 30-Day Adjunct Wellness Intervention for the Management of Extra-Articular Symptoms of Rheumatoid Arthritis: A Formative Study

S. Cole, Donna Rolin, A. Laster, 2022, Journal of evidence-based integrative medicine.

Osteoporosis care in the United States after declines in reimbursements for DXA.

L. Carbone, K. Saag, K. Johnson, 2010, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Does an adjustment to the dosing and timing of immunomodulatory drugs alter the immunogenicity of the COVID-19 vaccines in patients with autoimmune and inflammatory rheumatic disease (AIIRD)?

L. Calabrese, A. Laster, H. Gladue, 2022, RMD Open.

Central DXA utilization shifts from office‐based to hospital‐based settings among medicare beneficiaries in the wake of reimbursement changes

K. Saag, M. Morrisey, J. Curtis, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Characterization of a monoclonal antibody, RTE-21, that binds to keratohyalin granule-associated proteins in epithelial cells of human skin and thymus.

B. Haynes, A. Laster, 1986, Clinical immunology and immunopathology.

Enhanced prediction of fracture risk combining vertebral fracture status and BMD

H. Genant, E. Siris, J. Krege, 2007, Osteoporosis International.

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial.

B. Combe, H. Tony, C. Martín, 2012, Arthritis and rheumatism.

Clinical review: Clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry.

E. Lewiecki, E. Lewiecki, A. Laster, 2006, The Journal of clinical endocrinology and metabolism.

Dual-Energy X-Ray Absorptiometry

Andrew J Laster, A. Laster, 2014, North Carolina Medical Journal.

“Evidence-based” or “logic-based” medicine?

N. Watts, J. Bilezikian, P. Miller, 2010, Osteoporosis International.

Vertebral Fracture Assessment by dual-energy X-ray absorptiometry: insurance coverage issues in the United States. A White Paper of the International Society for Clinical Densitometry.

E. Lewiecki, A. Laster, E. M. Lewiecki, 2007, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

The geographic availability and associated utilization of dual-energy X-ray absorptiometry (DXA) testing among older persons in the United States

L. Carbone, K. Saag, M. Morrisey, 2009, Osteoporosis International.

Call for action: incorporating wellness practices into a holistic management plan for rheumatoid arthritis—going beyond treat to target

M. A. van de Laar, P. Taylor, I. de la Torre, 2021, RMD Open.

More bone density testing is needed, not less

J. Bilezikian, P. Miller, E. Lewiecki, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Patterns of Teriparatide and Sequential Antiresorptive Agent Treatment Among Elderly Female Medicare Beneficiaries

Jiannong Liu, Haifeng Guo, S. Gandra, 2021, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Longitudinal Trends in Use of Bone Mass Measurement Among Older Americans, 1999–2005

L. Carbone, R. Sepanski, K. Saag, 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.